RxDoctor Payments Data

Dimple Amin

Family · Gilbert, AZNPI 1982142659

Payments from drug & device makers

$5,757in general payments, 2019–2025

Across 396 payments — averaging $14.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Abbott$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$801
  • Protega Pharmaceutials Inc$259
  • Vertos Medical, Inc.$196
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$5,64098%
  • Education$1172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,757 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$99,606
Medicare patients
264
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide89$215,258
Xtampza ErOxycodone Myristate39$38,532
MovantikNaloxegol Oxalate51$23,000
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen672$16,521
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen445$12,992
Oxycodone Hcl745$11,528
Gabapentin590$9,954
BelbucaBuprenorphine Hcl23$8,621
Pregabalin341$8,305
Buprenorphine16$5,496
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl31$4,156
Cyclobenzaprine Hcl416$4,010
Diclofenac Sodium168$3,372
Tizanidine Hcl347$3,317
Lidocaine44$3,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$801$215,25889 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$1,064$47,15262 claims
Redhill Biopharma Inc.Movantik$169$23,00051 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate$160$11,452105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →